Mds Informaticki Inzenjering

Mds Informaticki Inzenjering company information, Employees & Contact Information

MDS is a domestic IT company with over five decades of experience in the development and implementation of advanced information systems. It is specialized in providing a wide range of IT services and solutions in software development, network infrastructure, data centers, cybersecurity, cloud services, and collaboration solutions. As a reliable partner to numerous institutions and companies in the domestic, regional, and global markets, MDS stands out with its focus on digital transformation, security, reliability, and long-term sustainability of technological solutions. The company comprises a team of over 150 certified professionals, whose knowledge and experience ensure top-quality services and a high degree of trust in every segment of the business.

Company Details

Employees
112
Founded
-
Address
Milutina Milankovica 7d, Belgrade,11070,serbia
Phone
381-11 3015536
Email
mds@mds.rs
Industry
It Services And It Consulting
NAICS
Computer Systems Design and Related Services
Other Computer Related Services
HQ
Belgrade
Looking for a particular Mds Informaticki Inzenjering employee's phone or email?

Mds Informaticki Inzenjering Questions

News

Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS - OncLive

Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS OncLive

(PDF) Analysis of myeloid neoplasms with isolated trisomy 19 reveals a novel MDS subgroup characterized by the presence of ring sideroblasts, fibrosis and SRSF2 and/or ASXL1 mutations - researchgate.net

(PDF) Analysis of myeloid neoplasms with isolated trisomy 19 reveals a novel MDS subgroup characterized by the presence of ring sideroblasts, fibrosis and SRSF2 and/or ASXL1 mutations researchgate.net

How I treat iron overload in adult MDS - ScienceDirect.com

How I treat iron overload in adult MDS ScienceDirect.com

How to use luspatercept and erythropoiesis-stimulating agents in low-risk myelodysplastic syndrome - Wiley Online Library

How to use luspatercept and erythropoiesis-stimulating agents in low-risk myelodysplastic syndrome Wiley Online Library

MD Anderson Research Highlights: ASH 2024 Special Edition - MD Anderson Cancer Center

MD Anderson Research Highlights: ASH 2024 Special Edition MD Anderson Cancer Center

SF3B1- mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms - Nature

SF3B1- mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms Nature

A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry - Taylor & Francis Online

A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry Taylor & Francis Online

Myelodysplastic Syndrome (MDS): Practice Essentials, Pathophysiology, Etiology - Medscape eMedicine

Myelodysplastic Syndrome (MDS): Practice Essentials, Pathophysiology, Etiology Medscape eMedicine

Understanding iron homeostasis in MDS: the role of erythroferrone - Frontiers

Understanding iron homeostasis in MDS: the role of erythroferrone Frontiers

Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) – “2021 update on diagnosis, risk-stratification, and management” - Wiley Online Library

Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) – “2021 update on diagnosis, risk-stratification, and management” Wiley Online Library

Management of patients with lower-risk myelodysplastic syndromes - Nature

Management of patients with lower-risk myelodysplastic syndromes Nature

SF3B1-Mutant Myelodysplastic Syndrome with Ringed Sideroblasts (MDS-RS) at the Single-Cell Level - ScienceDirect.com

SF3B1-Mutant Myelodysplastic Syndrome with Ringed Sideroblasts (MDS-RS) at the Single-Cell Level ScienceDirect.com

Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis | Leukemia - Nature

Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis | Leukemia Nature

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis - Nature

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis Nature

Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS-RS) but not in MDS/MPN-RS-T - Wiley Online Library

Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS-RS) but not in MDS/MPN-RS-T Wiley Online Library

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients | Blood Cancer Journal - Nature

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients | Blood Cancer Journal Nature

Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms - Nature

Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms Nature

SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis - Nature

SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis Nature

Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms | Blood Cancer Journal - Nature

Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms | Blood Cancer Journal Nature

Evolving MDS Treatment Options and the MEDALIST Trial - Docwire News

Evolving MDS Treatment Options and the MEDALIST Trial Docwire News

Approaches to the Diagnosis and Risk Stratification of MDS to Guide Precision Therapy - ASCO Daily News

Approaches to the Diagnosis and Risk Stratification of MDS to Guide Precision Therapy ASCO Daily News

COMMANDS Trial Demonstrates Benefit Across Mutations in RS-Positive LR-MDS - Targeted Oncology

COMMANDS Trial Demonstrates Benefit Across Mutations in RS-Positive LR-MDS Targeted Oncology

Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts - Nature

Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts Nature

U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions - Bristol Myers Squibb

U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions Bristol Myers Squibb

Efficacy of Luspatercept in Low-Risk Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis - ScienceDirect.com

Efficacy of Luspatercept in Low-Risk Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis ScienceDirect.com

Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosis - Frontiers

Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosis Frontiers

Molecular aberrations in myelodysplastic syndromes - Shah - 2021 - ADVANCES IN CELL AND GENE THERAPY - Wiley Online Library

Molecular aberrations in myelodysplastic syndromes - Shah - 2021 - ADVANCES IN CELL AND GENE THERAPY Wiley Online Library

SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome–Refractory Cytopenia With Multilineage Dysplasia - ScienceDirect.com

SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome–Refractory Cytopenia With Multilineage Dysplasia ScienceDirect.com

The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry - Taylor & Francis Online

The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry Taylor & Francis Online

SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process - Frontiers

SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process Frontiers

Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts - Nature

Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts Nature

ASCO 2023 – Bristol’s Commands data look good for Geron | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASCO 2023 – Bristol’s Commands data look good for Geron | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome - ScienceDirect.com

Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome ScienceDirect.com

A case of MDS/MPN overlap syndrome with ring sideroblasts and thrombocytosis: Tackling the quandary of thrombosis versus hemorrhage - Wiley Online Library

A case of MDS/MPN overlap syndrome with ring sideroblasts and thrombocytosis: Tackling the quandary of thrombosis versus hemorrhage Wiley Online Library

Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome - Nature

Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome Nature

Prevalence and Types of Myelodysplastic Syndromes (MDS) - Pharmacy Times

Prevalence and Types of Myelodysplastic Syndromes (MDS) Pharmacy Times

Myelodysplastic Syndrome Treatment & Pharmacologic Management - Cancer Therapy Advisor

Myelodysplastic Syndrome Treatment & Pharmacologic Management Cancer Therapy Advisor

Potential new therapy for MDS blood cancer - Knut och Alice Wallenbergs Stiftelse

Potential new therapy for MDS blood cancer Knut och Alice Wallenbergs Stiftelse

Transitioning from ESAs to EMAs in MDS Treatment - Targeted Oncology

Transitioning from ESAs to EMAs in MDS Treatment Targeted Oncology

Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa - Frontiers

Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa Frontiers

Recent Data Shed Further Light on the MDS Treatment Paradigm as the SOC Evolves - OncLive

Recent Data Shed Further Light on the MDS Treatment Paradigm as the SOC Evolves OncLive

Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patients - Wiley Online Library

Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patients Wiley Online Library

Upfront Therapy for Anemia in Lower-Risk Myelodysplastic Syndromes: Luspatercept for All or for Some? - ASCO Daily News

Upfront Therapy for Anemia in Lower-Risk Myelodysplastic Syndromes: Luspatercept for All or for Some? ASCO Daily News

Luspatercept in MDS Promotes Transfusion Independence and Anemia Response - Targeted Oncology

Luspatercept in MDS Promotes Transfusion Independence and Anemia Response Targeted Oncology

Comparison of the 2022 ICC and Who Classification Systems of Myelodysplastic Neoplasms - ScienceDirect.com

Comparison of the 2022 ICC and Who Classification Systems of Myelodysplastic Neoplasms ScienceDirect.com

Monocytosis May Be a Sign of Trouble for Patients with Myelodysplastic Syndromes - MedPage Today

Monocytosis May Be a Sign of Trouble for Patients with Myelodysplastic Syndromes MedPage Today

FDA Approves Luspatercept to Treat Anemia in Patients with Lower-Risk MDS - CancerNetwork

FDA Approves Luspatercept to Treat Anemia in Patients with Lower-Risk MDS CancerNetwork

Dr Komrokji on the Classification of Patients With Myelodysplastic Syndromes - OncLive

Dr Komrokji on the Classification of Patients With Myelodysplastic Syndromes OncLive

Reblozyl Approved as First-Line Treatment for Anemia in Lower-Risk Myelodysplastic Syndromes - Medical Professionals Reference

Reblozyl Approved as First-Line Treatment for Anemia in Lower-Risk Myelodysplastic Syndromes Medical Professionals Reference

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial - The Lancet

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial The Lancet

FDA Approves First Erythroid Maturation Agent to Treat Anemia in Patients with Myelodysplastic - Docwire News

FDA Approves First Erythroid Maturation Agent to Treat Anemia in Patients with Myelodysplastic Docwire News

Features and Outcomes in Myelodysplastic Syndrome, Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis - Hematology Advisor

Features and Outcomes in Myelodysplastic Syndrome, Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis Hematology Advisor

A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation - Frontiers

A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation Frontiers

Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML - Nature

Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML Nature

Associations of Mutations in Spliceosome Genes With Ring Sideroblasts Verified in Myelodysplastic Syndromes - Hematology Advisor

Associations of Mutations in Spliceosome Genes With Ring Sideroblasts Verified in Myelodysplastic Syndromes Hematology Advisor

‘BMS’ Reblozyl to ease blood transfusion burden for MDS-RS patients’ - koreabiomed.com

‘BMS’ Reblozyl to ease blood transfusion burden for MDS-RS patients’ koreabiomed.com

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts - Nature

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts Nature

A three-dimensional in vitro model of erythropoiesis recapitulates erythroid failure in myelodysplastic syndromes - Nature

A three-dimensional in vitro model of erythropoiesis recapitulates erythroid failure in myelodysplastic syndromes Nature

FDA Approves Reblozyl for Anemia in Patients With Myelodysplastic Syndromes - Medical Professionals Reference

FDA Approves Reblozyl for Anemia in Patients With Myelodysplastic Syndromes Medical Professionals Reference

FDA Approves Luspatercept for MDS-Associated Anemia - OncLive

FDA Approves Luspatercept for MDS-Associated Anemia OncLive

Diagnostic algorithm for lower-risk myelodysplastic syndromes - Nature

Diagnostic algorithm for lower-risk myelodysplastic syndromes Nature

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes - The New England Journal of Medicine

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes The New England Journal of Medicine

ASCO: Bristol Myers' $4B plan for Reblozyl takes shape in blood cancer anemia—with one caveat - Fierce Pharma

ASCO: Bristol Myers' $4B plan for Reblozyl takes shape in blood cancer anemia—with one caveat Fierce Pharma

Subgroup Analyses of COMMANDS Trial Favor Luspatercept in MDS - Targeted Oncology

Subgroup Analyses of COMMANDS Trial Favor Luspatercept in MDS Targeted Oncology

Genetics and Ring Sideroblasts Impact ESA-Refractory Anemia in MDS - Targeted Oncology

Genetics and Ring Sideroblasts Impact ESA-Refractory Anemia in MDS Targeted Oncology

FDA Approves Luspatercept as First-Line Anemia Treatment in Patients With Lower-Risk MDS - AJMC

FDA Approves Luspatercept as First-Line Anemia Treatment in Patients With Lower-Risk MDS AJMC

SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment - Nature

SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment Nature

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis - Frontiers

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis Frontiers

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts - Wiley Online Library

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts Wiley Online Library

Diagnosed With a Rare Disease, This Woman Found a Way Forward - Prevention

Diagnosed With a Rare Disease, This Woman Found a Way Forward Prevention

Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis - Wiley Online Library

Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis Wiley Online Library

Bristol Myers, Acceleron's Reblozyl moves closer to blockbusterland with new blood disorders nod - Fierce Pharma

Bristol Myers, Acceleron's Reblozyl moves closer to blockbusterland with new blood disorders nod Fierce Pharma

BMS anemia drug Reblozyl arrives in Korea swiftly - koreabiomed.com

BMS anemia drug Reblozyl arrives in Korea swiftly koreabiomed.com

Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1 -mutant myelodysplastic syndromes - Nature

Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1 -mutant myelodysplastic syndromes Nature

(PDF) Perls’ Stain Guidelines from the French-Speaking Cellular Hematology Group (GFHC) - researchgate.net

(PDF) Perls’ Stain Guidelines from the French-Speaking Cellular Hematology Group (GFHC) researchgate.net

BMS Korea gets regulatory nods for 2 myelofibrosis treatments - koreabiomed.com

BMS Korea gets regulatory nods for 2 myelofibrosis treatments koreabiomed.com

(PDF) Megaloblastic Anaemia With Ring Sideroblasts Not Always Mds - researchgate.net

(PDF) Megaloblastic Anaemia With Ring Sideroblasts Not Always Mds researchgate.net

(PDF) Causes and Pathophysiology of Acquired Sideroblastic Anemia - researchgate.net

(PDF) Causes and Pathophysiology of Acquired Sideroblastic Anemia researchgate.net

(PDF) Understanding Sideroblastic Anemia: An Overview of Genetics, Epidemiology, Pathophysiology and Current Therapeutic Options - researchgate.net

(PDF) Understanding Sideroblastic Anemia: An Overview of Genetics, Epidemiology, Pathophysiology and Current Therapeutic Options researchgate.net

Almost 50% of Nifty 50 CEOs, MDs earn over Rs 20 crore a year - The Economic Times

Almost 50% of Nifty 50 CEOs, MDs earn over Rs 20 crore a year The Economic Times

Sebi fines NSE, 2 ex-MDs total Rs 1.5 crore for co-lo scam - Times of India

Sebi fines NSE, 2 ex-MDs total Rs 1.5 crore for co-lo scam Times of India

Sebi fines NSE Rs 1,100 crore, bans two ex-MDs in brokers’ scam - Times of India

Sebi fines NSE Rs 1,100 crore, bans two ex-MDs in brokers’ scam Times of India

Leaving bond service midway: Rs 40 lakh penalty set for MD, MS, MDS doctors, Rs 20 lakh for PG Diploma in ... - Medical Dialogues

Leaving bond service midway: Rs 40 lakh penalty set for MD, MS, MDS doctors, Rs 20 lakh for PG Diploma in ... Medical Dialogues

15 percent Stipend Hike Announced for MBBS Interns, PG medical, MDS, Super-Speciality Doctors in... - Medical Dialogues

15 percent Stipend Hike Announced for MBBS Interns, PG medical, MDS, Super-Speciality Doctors in... Medical Dialogues

MD, MS, Diploma, DNB, MDS Admissions in UP: DGME Releases Time Schedule - Medical Dialogues

MD, MS, Diploma, DNB, MDS Admissions in UP: DGME Releases Time Schedule Medical Dialogues

Leaving bond service midway: Rs 40 lakh penalty set for MD, MS, MDS doctors, Rs 20 lakh for PG diploma in ... - Medical Dialogues

Leaving bond service midway: Rs 40 lakh penalty set for MD, MS, MDS doctors, Rs 20 lakh for PG diploma in ... Medical Dialogues

Rs 5,7 Mds à Betamax: l'extension du délai réclamée par la STC agréée - lexpress.mu

Rs 5,7 Mds à Betamax: l'extension du délai réclamée par la STC agréée lexpress.mu

Top Mds Informaticki Inzenjering Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant